Drug Trial Radar · NCT05924750
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Aug 2, 2023
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at the recommended dose in phase Ia to determine the recommended dose in phase II clinical study (RP2D).
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Interventions
BL-M11D1Drug
Administration by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to 28 days after the first dose
- Phase Ia: Maximum tolerated dose (MTD)Time frame: Up to 28 days after the first dose
- Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to 28 days after the first dose
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China · Not yet recruiting
Beijing Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Institute of Hematology, the First Hospital of Harbin
Haerbin, Heilongjiang, China · Not yet recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shangdong, China · Not yet recruiting
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
West China Hospital,Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.